GlaxoSmithKline of the United Kingdom and Medicago of Canada said on Tuesday that they had seen encouraging results in a large-scale experiment using a prospective Covid-19 vaccine.
A Plant-Derived COVID Vaccine Shows Positive Results
GlaxoSmithKline (GSK) of the United Kingdom and Medicago of Canada said on Tuesday that they had seen encouraging results in a large-scale experiment using a prospective Covid-19 vaccine, although the studies were conducted before the Omicron variant surfaced.
The Phase 3 study found that “the overall vaccine effectiveness rate against all variants of SARS-COV-2 was 71%," the two firms said in a statement referring to the new coronavirus by its technical name.
Additionally, it was effective against the “globally prevalent Delta variant" at a rate of 75.3 percent.
However, they continued, the Omicron variant was not circulating at the time of the research, which included 24,000 individuals from six countries: Canada, the United States, the United Kingdom, Mexico, Argentina, and Brazil.
Source - Bassett Healthcare Network
The data are not comparable to previous vaccine trials, as the majority of which were conducted while the underlying virus strain was still circulating.
“During the study, no related serious adverse events were reported, and reactogenicity (side effects) was generally mild to moderate and transient; symptoms lasting on average only one to three days,“ the companies said.
Only a few severe virus infections were found among trial participants, all of which occurred in the group that received the placebo rather than the vaccines.
Medicago claims that the vaccine, which stimulates the immune system via the use of particles that replicate the features of viruses, is based on plants.
“Because the virus-like particles lack core genetic material, they are non-infectious and unable to replicate,“ the company said.
“Based on these results, Medicago will imminently seek regulatory approval from Health Canada as part of its rolling submission,“ GSK and Medicago said, although “the vaccine candidate is not yet approved by any regulatory authority”.
Additionally, they have applied for permission from US and UK authorities.
GSK is also exploring potential treatments for Covid-19 in collaboration with France’s Sanofi, Germany’s CureVac, and South Korea’s SK Bioscience.
One, a monoclonal antibody treatment designed in partnership with California-based Vir Biotechnology, was authorised this week by British authorities.
Source – The Sun Daily